Ahmedabad, April 18,2014 –
Ahmedabad-based pharmaceutical player Cadila Healthcare Limited today informed that the company and its US subsidiary, Zydus Pharmaceuticals (USA), Inc., has entered into a settlement agreement with Depomed Inc to settle a patent dispute regarding Gralise tablets.
The Cadila Pharmaceuticals informed that it “has entered into a settlement agreement with Depomed Inc to settle the ongoing patent infringement litigation related to Gralise (gabapentin) tablets.”
In a statement released on Tuesday, the company said, “The settlement permits Cadila and Zydus to begin selling generic versions of Gralise 300 mg and 600 mg tablets on January 1, 2024, or earlier under certain circumstances. Other terms of the settlement were not disclosed.”
The agreement is subject to review by the US Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the U.S. District Court for the District of New Jersey.
Cadila Healthcare shares ended positive at Rs 974.5 with marginal gain of 0.8 per cent on the Bombay Stock Exchange on Tuesday.
New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…